In August 2019, Elanco Animal Health Incorporated (NYSE: ELAN) entered into an agreement with Bayer AG (ETR: BAYN) to acquire its animal health business in a transaction valued at US$7.6 billion. The transaction is expected to close in mid-2020, subject to regulatory approvals and other customary closing conditions.
Duff & Phelps served as financial advisor to the board of directors of Elanco and provided a fairness opinion in connection with the transaction. With a reputation built over decades, Duff & Phelps’ Fairness Opinion practice delivers high quality financial advice and opinions that withstand the most rigorous scrutiny. In the EMEA region – Duff & Phelps rendered fairness opinions aggregating more than €13bn in deal value, according to Thomson Reuters’ M&A Review in 2018. Additionally, earlier this year Duff & Phelps received its license from the Swiss Takeover Commission, which entitles it to issue fairness opinions under Swiss public takeover law.
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life — all to advance the health of animals, people and the planet. Paul, Weiss, Rifkind, Wharton & Garrison LLP and Hengeler Mueller acted as legal counsel to Elanco.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.
Comprehensive support throughout mergers and acquisitions and other corporate transactions.
Middle-market M&A advisory differentiated by industry expertise and superior deal execution.
Transaction Advisory Services
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Financial Sponsors Group
Dedicated coverage and access to M&A deal-flow for financial sponsors.
Private Capital Markets
Senior, subordinated and mezzanine debt and venture/private equity for a wide range of transactions.
Fairness and Solvency Opinions
Independent opinions for boards of directors and special committees.
Valuation and consulting for financial reporting, federal, state and local tax, investment and risk management purposes.
Property tax, site selection, transfer pricing, sales and use tax and unclaimed property advisory.
European Travel Update – Q3 2020
Mexico Capital Markets Insights – Summer 2020
Japan Transaction Insights – Summer 2020
The Future of Manufacturing: Reshoring and the Global Supply Chain
Gregory Burkart Discusses the ‘Tipping Point’ for Reshoring Production to the U.S.
Duff & Phelps Featured in Bloomberg BNA Transfer Pricing Forum: Transfer Pricing Practice During COVID-19
Duff & Phelps Transfer Pricing Featured in Bloomberg Tax Discussing Implementation of the OECD’s Transaction Net Margin Method in Brazil
Sin Yee Koh Featured in Accuity Podcast on Fintechs & Financial Crime Compliance Best Practices